.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,440,656

« Back to Dashboard

Details for Patent: 6,440,656

Title: Methods for the inhibition of respiratory syncytial virus transmission
Abstract:Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107.times.178.times.4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-178, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections.
Inventor(s): Bolognesi; Dani Paul (Durham, NC), Matthews; Thomas James (Durham, NC), Wild; Carl T. (Durham, NC), Barney; Shawn O'Lin (Cary, NC), Lambert; Dennis Michael (Cary, NC), Petteway, Jr.; Stephen Robert (Cary, NC)
Assignee: Trimeris, Inc. (Durham, NC)
Filing Date:Jun 07, 1994
Application Number:08/255,208
Claims:1. A method for the inhibition of transmission of a respiratory syncytial virus to a cell, comprising contacting the cell with an effective concentration of an isolated peptide consisting of an amino acid sequence of a 16 to 39 amino acid residue region of a respiratory syncytial virus protein for an effective period of time, wherein: (a) said region is recognized by an ALLMOTI5, 107.times.178.times.4, or PLZIP sequence search motif; (b) said peptide further comprises an amino terminal X, and a carboxy terminal Z in which: X comprises an amino group, an acetyl group, a 9-fluorenylmethoxy-carbonyl group, a hydrophobic group, or a macromolecular carrier group; and Z comprises a carboxyl group, an amido group, a hydrophobic group, or a macromolecular carrier group; and (c) fusion of the virus to the cell is inhibited.

2. A method for the inhibition of transmission of a respiratory syncytial virus to a cell, comprising contacting the cell with an effective concentration of a peptide for an effective period of time, wherein the peptide has the formula: X-FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE-Z (SEQ ID NO:68); X-DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL-Z (SEQ ID NO:101); X-YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL-Z (SEQ ID NO:103); X-LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN-Z (SEQ ID NO:104); X-VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV-Z (SEQ ID NO:105); X-FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN-Z (SEQ ID NO:106); X-PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA-Z (SEQ ID NO:107); X-SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG-Z (SEQ ID NO:108); X-DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK-Z (SEQ ID NO:109); X-FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST-Z (SEQ ID NO:110); or X-DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT-Z (SEQ ID NO:111) in which: amino acid residues are presented by the single-letter code; X comprises an amino group, an acetyl group, a 9-fluoromethyoxymethyl-carbonyl group, a hydrophobic group, or a macromolecular carrier group; Z comprises a carboxyl group, an amido group, a hydrophobic group, or a macromolecular carrier group; and wherein fusion of the virus to the cell is inhibited.

3. The method of claim 2, wherein the peptide has the formula: X-DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL-Z (SEQ ID NO. 101).

4. The method of claim 2, wherein the peptide has the formula: X-YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL-Z (SEQ ID NO. 103).

5. The method of claim 2, wherein the peptide has the formula: X-LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN-Z (SEQ ID NO. 104).

6. The method of claim 2, wherein the peptide has the formula: X-VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV-Z (SEQ ID NO. 105).

7. The method of claim 2, wherein the peptide has the formula: X-FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN-Z (SEQ ID NO. 106).

8. The method of claim 2, wherein the peptide has the formula: X-PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA-Z (SEQ ID NO. 107).

9. The method of claim 2, wherein the peptide has the formula: X-SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG-Z (SEQ ID NO. 108).

10. The method of claim 2, wherein the peptide has the formula: X-DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK-Z (SEQ ID NO. 109).

11. The method of claim 2, wherein the peptide has the formula: X-FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST-Z (SEQ ID NO. 110).

12. The method of claim 2, wherein the peptide has the formula: X-DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT-Z (SEQ ID NO. 111).

13. The method of claim 2, wherein the peptide has the formula: X-FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE-Z (SEQ ID NO. 68).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc